Glutamate release inhibition ineffective in levodopa-induced motor complications
Glutamate release inhibition ineffective in levodopa-induced motor complications
复制标题
DOI：
10.1002/mds.20976
复制
发表时间：
2006-09-01
影响因子：
8.6
通讯作者：
Chase, Thomas N.
中科院分区：
文献类型：
--
作者：
Bara-Jimenez, William;Dimitrova, Tzvetelina D.;Chase, Thomas N.
据报道，各种谷氨酸受体拮抗剂对帕金森病（PD）的益处促使对15例中晚期患者中假定的谷氨酸释放抑制剂的抗运动障碍作用进行评估。在一项为期3周的双盲概念验证研究中，利鲁唑（200mg /天）未能改变帕金森病或左旋多巴诱导的运动并发症的严重程度。广泛抑制谷氨酸介导的突触传递的相反作用可能限制这种方法治疗帕金森病的有效性。(c) 2006年运动障碍协会。
Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3-week, double-blind, proof-of-concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa-induced motor complication severity. Opposing effects of a generalized inhibition of glutamate-mediated synaptic transmission may limit the usefulness of this approach to treat PD. (c) 2006 Movement Disorder Society.